Showing results (191-200 of 266) with videos related to
Sort By:
Pageof 27
Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.Cancer Research|March 31, 2011
Differentiation of NUT midline carcinoma by epigenomic reprogrammingBrian E Schwartz, Matthias D Hofer, Madeleine E Lemieux, et al.JCO Precision Oncology|September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)Margaret E Macy, Rajen Mody, Joel M Reid, et al.JAMA|March 15, 2012
Association of age at diagnosis and genetic mutations in patients with neuroblastomaNai-Kong V Cheung, Jinghui Zhang, Charles Lu, et al.Cancer|July 30, 2019
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology GroupRyan D Roberts, Michael M Lizardo, Damon R Reed, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007Ching-Hon Pui, Deqing Pei, Alberto S Pappo, et al.JNCI Cancer Spectrum|January 17, 2025
Head and neck paraganglioma in Pacak-Zhuang syndromeJared S Rosenblum, Yasemin Cole, Danielle Dang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH TrialOlive S Eckstein, Carl E Allen, P Mickey Williams, et al.JCO Precision Oncology|June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialKieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 4, 2017
Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategyAlanna J Church, Monica L Calicchio, Valentina Nardi, et al.Pageof 27